Would you consider replacing ibrutinib with acalabrutinib or zanubrutinib in the TRIANGLE regimen for MCL in a patient with atrial fibrillation or high risk coronary syndromes who is otherwise fit for aggressive induction therapy?

Would you replace ibrutinib with acalabrutinib or zanubrutinib in the TRIANGLE regimen for MCL in a patient with atrial fibrillation or high risk coronary syndromes otherwise eligible for aggressive induction?

• Yes, I would replace ibrutinib with acalabrutinib
• Yes, I would replace ibrutinib with zanubrutinib
• Yes, I would replace ibrutinib with either acalabrutinib or zanubrutinib
• No, I would still start out using ibrutinib and adjust if toxicity ensues
• No, I have not adopted the TRIANGLE regimen in MCL
• Other